Evidence map›Paper›PMID 38389797›Full record

ReviewFrontiers in nutrition2024

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins.

Xiaoyue Kong, Wei Wang, Yizhi Zhong, Nan Wang, Kaiwen Bai, Yi Wu, Qianhui Qi, Yu Zhang, Xingquan Liu, Junran Xie

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Xiaoyue Kong *College of Food and Health, Zhejiang Agriculture and Forestry University, Hangzhou, China.
Wei WangSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China.
Yizhi Zhong *Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Nan WangCollege of Biology and Environmental Engineering, Zhejiang Shuren University, Hangzhou, China.
Kaiwen BaiSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China.
Yi WuSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China.
Qianhui QiSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China.
Yu ZhangInstitute of Quality and Standard for Agriculture Products, Zhejiang Academy of Agricultural Science, Hangzhou, China.
Xingquan LiuCollege of Food and Health, Zhejiang Agriculture and Forestry University, Hangzhou, China.
Junran XieDepartment of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang University of Science and Technology · CNZhejiang A & F University · CNZhejiang University · CNZheJiang Academy of Agricultural Sciences · CNZhejiang Shuren University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), is spreading worldwide. Although the COVID-19 epidemic has passed its peak of transmission, the harm it has caused deserves our attention. Scientists are striving to develop medications that can effectively treat COVID-19 symptoms without causing any adverse reactions. SARS-CoV-2 inhibitory peptides derived from animal proteins have a wide range of functional activities in addition to safety. Identifying animal protein sources is crucial to obtaining SARS-CoV-2 inhibitory peptides from animal sources. This review aims to reveal the mechanisms of action of these peptides on SARS-CoV-2 and the possibility of animal proteins as a material source of SARS-CoV-2 inhibitory peptides. Also, it introduces the utilization of computer-aided design methods, phage display, and drug delivery strategies in the research on SARS-CoV-2 inhibitor peptides from animal proteins. In order to identify new antiviral peptides and boost their efficiency, we recommend investigating the interaction between SARS-CoV-2 inhibitory peptides from animal protein sources and non-structural proteins (Nsps) using a variety of technologies, including computer-aided drug approaches, phage display techniques, and drug delivery techniques. This article provides useful information for the development of novel anti-COVID-19 drugs.

Indexed as

computer-aided design methodsdrug delivery strategiesefficacymechanismspeptides derived from animal proteinsSARS-CoV-2

Identifiers

PMID38389797
PMCPMC10883054
OpenAlexW4391609162

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.